Drug Class Detail

Drug Class BRAF Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ASN003 BRAF Inhibitor 18 PIK3CA inhibitor 14 PIK3CG inhibitor 8 ASN003 is a small molecule inhibitor of BRAF, PIK3CA, and PIK3CG, which may result in inhibition of cell proliferation and antitumor activity (J Clin Oncol 35, 2017 (suppl; abstr e14102)).
SKLB646 BRAF Inhibitor 18 CRAF Inhibitor 10 SRC Inhibitor 26 VEGFR2 Inhibitor 34 SKLB646 is a multi-kinase inhibitor with activity against Src, Kdr (Vegfr2), Braf and Craf, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 26721945).
PLX7904 BRAF Inhibitor 18 PLX7904 is a small molecule inhibitor that preferentially inhibits BRAF V600E over wild-type BRAF and CRAF without activating MAPK signaling, therefore leads to growth inhibition in tumor cells (PMID: 26466569).
EBI-907 BRAF Inhibitor 18 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 FGFR3 Inhibitor 12 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 EBI-907 is a multi-kinase inhibitor that inhibits BRAF V600E, FGFR1-3, RET, KIT, and PDGFRb, which results in tumor growth inhibition (PMID: 26810733).
PLX4720 BRAF Inhibitor 18 PLX4720 is a 7-azaindole derivative and RAF kinase inhibitor with greater affinity for BRAF V600E than BRAF wild-type (PMID: 18287029).
SB590885 BRAF Inhibitor 18 SB590885 is a RAF kinase inhibitor with greater specificity for BRAF over CRAF and significant activity against BRAF V600E (PMID: 17145850).
GDC0879 GDC-0879 BRAF Inhibitor 18 CRAF Inhibitor 10 GDC0879 is a selective small molecular inhibitor of BRAF and CRAF (RAF1), which inhibits survival of tumor cells (PMID: 19276360).
Regorafenib Stivarga BAY 73-4506 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR Inhibitor (Pan) 29 VEGFR2 Inhibitor 34 Stivarga (regorafenib) is an inhibitor of several kinases including VEGFR, RET, KIT, PDGFR and RAF, thereby inhibiting tumor angiogenesis and tumor cell proliferation (PMID: 24756792). Stivarga (regorafenib) is FDA approved for colorectal cancer, hepatocellular carcinoma, and GIST (FDA.gov).
Encorafenib Braftovi LGX818 BRAF Inhibitor 18 Braftovi (encorafenib) is an inhibitor of Raf kinase with selective activity against BRAF V600E, resulting in growth inhibition (PMID: 24864047). Braftovi (encorafenib) in combination with Mektovi (binimetinib) is FDA approved for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (FDA.gov).
PLX8394 BRAF Inhibitor 18 CRAF Inhibitor 10 PLX8394 is a RAF inhibitor that inhibits wild-type and mutant BRAF, as well as CRAF, and does not paradoxically activate MAPK signaling, potentially resulting in decreased proliferation of BRAF-mutant tumor cells (PMID: 26466569, PMID: 24283590).
BGB-283 BRAF Inhibitor 18 EGFR Inhibitor (Pan) 38 BGB-283 is a dual RAF kinase and EGFR inhibitor, which may lead to decreased tumor cell proliferation and reduced growth of tumors with activation of BRAF and/or EGFR (PMID: 26208524).
BI 882370 BRAF Inhibitor 18 BI 882370 is a Raf kinase inhibitor with potent activity against the inactive conformation of Braf and may result in tumor regression (PMID: 26916115).
RO5212054 PLX3603 BRAF Inhibitor 18 PLX3603 (RO5212054) is a BRAF inhibitor (PMID: 23617957, PMID: 25204436).
RXDX-105 AC013773|CEP-32496 ABL Inhibitor (pan) 8 ABL1 Inhibitor 4 BCR-ABL Inhibitor 23 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 RXDX-105 (CEP-32496) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199).
RAF709 BRAF Inhibitor 18 CRAF Inhibitor 10 RAF709 is an ATP-competitive inhibitor that inhibits both BRAF monomers and RAF dimers, resulting in growth inhibition in tumor cells (PMID: 29343524).
HM95573 BRAF Inhibitor 18 CRAF Inhibitor 10 HM95573 selectively inhibits BRAF and CRAF, resulting in growth inhibition in tumor cells (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).
RAF265 BRAF Inhibitor 18 CRAF Inhibitor 10 VEGFR2 Inhibitor 34 RAF265 inhibits the activities of several intracellular kinases, including BRAF(V600E), BRAF(wild type), c-RAF (RAF1), VEGF receptor 2 (VEGFR2/KDR), platelet-derived growth factor receptor (PDGFR), colony-stimulating factor (CSF)1R, RET and c-KIT, SRC, STE20, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death (PMID: 22351689; NCI Drug Dictionary).
Dabrafenib Tafinlar GSK2118436 BRAF Inhibitor 18 Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in inhibition of tumor cell proliferation (NCI Drug Dictionary). Tafinlar (dabrafenib) is FDA approved for BRAF V600E positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, and BRAF V600E-mutant anaplastic thyroid cancer (FDA.gov).